Combination of antiviral immnunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections

Antiviral Research

Volumn 32, Issue 3, 1996, Pages 165-171

  Smee, Donald F ^a   Sidwell, Robert W ^a   Barnett, Bill B ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Cidofovir; Cytomegalovirus; Ganciclovir; Immunotoxin; SCID mice

Indexed keywords

ACETONITRILE; AMILORIDE; BOLDENONE; CHLORTALIDONE; CLOSTEBOL ACETATE; DODECYL SULFATE SODIUM; DYDROGESTERONE; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; METANDIENONE; METHYLTESTOSTERONE; PROGESTERONE; STEROID; TESTOSTERONE; TESTOSTERONE PROPIONATE; ANTIVIRUS AGENT; CIDOFOVIR; CYTOSINE; DRUG DERIVATIVE; GANCICLOVIR; GEL PROTEIN, GELONIUM MULTIFLORUM; IMMUNOTOXIN; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; RICIN; VEGETABLE PROTEIN;

ANALYTIC METHOD; ARTICLE; DRUG DETERMINATION; LIQUID CHROMATOGRAPHY; MODEL; PRIORITY JOURNAL; ANIMAL; BETAHERPESVIRINAE; CELL CULTURE; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG COMBINATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; MOUSE; MOUSE MUTANT; VIROLOGY;

CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DRUG THERAPY, COMBINATION; GANCICLOVIR; IMMUNOTOXINS; MICE; MICE, SCID; MUROMEGALOVIRUS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PLANT PROTEINS; RICIN; TUMOR CELLS, CULTURED;

EID: 0030273872     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(95)00986-8     Document Type: Article

References (21)

1. Barnett, B.B., Burns, N.J., Park, K.J., Dawson, M.I., Kende, M. and Sidwell, R.W. (1991) Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro. Antiviral Res. 15, 125-138.
2. Barnett, B.B., Smee, D.F., Malek, S.M. and Sidwell, R.W. (1995) Selective cytotoxicity towards cytomegalovirus-infected cells by immunotoxins consisting of gelonin linked to anti-cytomegalovirus antibody. Antiviral Res. 28, 93-100.
3. Barnett, B.B., Smee, D.F., Malek, S.M. and Sidwell, R.W. (1996) Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells. Antimicrob. Agents Chemother. 40, 470-472.
4. Emanuel, D.J. (1991) Uses of immunotherapy for control of human cytomegalovirus-associated diseases. Transplant. Proc. 23 (Suppl. 3), 144-146.
5. Freitas, V.R., Smee, D.F., Chernow, M., Boehme, R. and Matthews, T.R. (1985) Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob. Agents Chemother. 28, 240-245.
6. Lalezari, J.P., Drew, W.L., Glutzer, E., James, C., Miner, D., Flaherty, J., Fisher, P.E., Cundy, K., Hannigan, J., Martin, J.C. and Jaffe, H.S. (1995) (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171, 788-796.
7. Laskin, O.L., Cederberg, D.M., Mills, J., Eron, L.J., Mildvan, D. and Spector, S.S. (1987) Ganciclovir for the treatment and suppression of serious infections caused by cytomegaloviruses. Am. J. Med. 83, 201-207.
8. Pincus, S.H., Wehrly, K. and Chesebro, B. (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J. Immunol. 142, 3070-3075.
9. Polis, M.A., Spooner, K.M., Baird, B.F., Manischewitz, J.F., Jaffe, H.S., Fisher, P.E., Falloon, J., Davey Jr., R.T., Kovacs, J.A., Walker, R.E., Whitcup, S.M., Nussenblatt, R.B., Lane, H.C. and Masur, H. (1995) Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39, 882-886.
10. Pritchard, M.N. and Shipman Jr., C. (1990) A three-dimensional model to analyze drug drug interactions. Antiviral Res. 14, 181-206.
11. Reed, L.J. and Muench, M. (1938) A simple method of estimating fifty percent end points. Am. J. Hyg. 27, 493-498.
12. Rubin, R.H. (1990) Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12 (Suppl. 7), S754-S766.
13. Schinazi, R.F., Peters, J., Williams, C.C., Chance, D. and Nahmias, A.J. (1982) Effect of combinations of acyclovir with vidarabine or its 5′-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob. Agents Chemother. 22, 499-507.
14. Schooley, R.T. (1990) Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev. Infect. Dis. 12 (Suppl. 7), S811-S819.
15. Selgrade, M.K., Nedrug, J.G., Collier, A.M. and Gardner, D.E. (1981) Effects of cell source, mouse strain, and immunosuppressive treatment on production of virulent and attenuated murine cytomegalovirus. Infect. Immun. 33, 840-847.
16. Smee, D.F., Morris, J.L.B., Barnard, D.L. and Van Aerschot, A. (1992a) Selective inhibition of arthropod-borne and arenaviruses in vitro by 3′-fluoro-3′-deoxyadenosine. Antiviral Res. 18, 151-162.
17. Smee, D.F., Morris, J.L.B., Leonhardt, J.A., Mead, J.R., Holy, A. and Sidwell, R.W. (1992b) Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC), interferon, and bropirimine. Antimicrob. Agents Chemother. 36, 1837-1842.
18. Smee, D.F., Sugiyama, S.T., Sidwell, R.W. and Barnett, B.B. (1995) Effects of monoclonal antibody combined with ganciclovir or (S)-1-[3-hydroxy-(2-phosphonyl-methoxy)-propyl]cytosine against murine cytomegalovirus infections in cell culture and in severe combined immunodeficient mice. Chemotherapy 41, 141-148.
19. Tenschert, W., Gonnermann, D., Meyer-Moldenhauer, W.-H., Cremashi, L. and Huland, H. (1993) Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment? Transplant. Proc. 25, 3256-3258.
20. Walmsley, S.L., Chew, E., Fanning, M.M., Read, S.E., Vellend, H., Salit, I. and Rachlis, A. (1988) Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J. Infect. Dis. 157, 569-572.
21. Yow, M.D. (1989) Congenital cytomegalovirus disease: a NOW problem. J. Infect. Dis. 159, 163-167.